Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Luciana Vinti, Daria Pagliara, Salvatore Buffardi, Valentina Di Ruscio, Francesca Stocchi, Elena Mariggiò, Rosanna Parasole, Antonia Di Matteo, Fara Petruzziello, Valeria Paganelli, Rita De Vito, Francesca Del Bufalo, Luisa Strocchio, Franco Locatelli

Research output: Contribution to journalArticle

Abstract

Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalPEDIATRIC BLOOD & CANCER
Volume69
DOIs
Publication statusPublished - 2022

Keywords

  • brentuximab vedotin
  • Hodgkin lymphoma
  • relapse
  • pediatric
  • refractory
  • immunotherapy

Fingerprint

Dive into the research topics of 'Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this